Previous Article | Next Article ![]()
Journal of Virology, July 2004, p. 7360-7368, Vol. 78, No. 14
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.14.7360-7368.2004
Vineet N. KewalRamani,2 Ji Ming Wang,3 Robert Blumenthal,1 and Anu Puri1*
Laboratory of Experimental and Computational Biology,1 HIV-Drug Resistance Program,2 Laboratory of Molecular Immunoregulation, Center for Cancer Research, NCI-Frederick, National Institutes of Health, Frederick, Maryland 217023
Received 28 January 2004/ Accepted 1 March 2004
GM3, a major ganglioside of T lymphocytes, promotes human immunodeficiency virus type 1 (HIV-1) entry via interactions with HIV-1 receptors and the viral envelope glycoprotein (Env). Increased GM3 levels in T lymphocytes and the appearance of anti-GM3 antibodies in AIDS patients have been reported earlier. In this study, we investigated the effect of GM3 regulation on HIV-1 entry by utilizing a mouse cell line (B16F10), which expresses exceptionally high levels of GM3. Strikingly, B16 cells bearing CD4, CXCR4, and/or CCR5 were highly resistant to CD4-dependent HIV-1 Env-mediated membrane fusion. In contrast, these targets supported membrane fusion mediated by CD4-requiring HIV-2, SIV, and CD4-independent HIV-1 Envs. Coreceptor function was not impaired by GM3 overexpression as indicated by Ca2+ fluxes mediated by the CXCR4 ligand SDF-1
and the CCR5 ligand MIP-1ß. Reduction in GM3 levels of B16 target cells resulted in a significant recovery of CD4-dependent HIV-1 Env-mediated fusion. We propose that GM3 in the plasma membrane blocks HIV-1 Env-mediated fusion by interfering with the lateral association of HIV-1 receptors. Our findings offer a novel mechanism of interplay between membrane lipids and receptors by which host cells may escape viral infections.
Present address: HIV-Drug Resistance Program, NCI-Frederick, NIH, Frederick, MD 21702.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|